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Introduction {#cjp288-sec-0001}
============

Protein glycosylation is a major posttranslational modification in mammalian cells. Aberrant glycosylation is frequently observed in various diseases, including cancer. The altered glycosylation pattern may result in different protein folding and biological functions [1](#cjp288-bib-0001){ref-type="ref"}. The glycosylation status of a cell is dynamic and alters upon oncogenesis, whereby cancer cells, compared to their healthy counterparts, express more branched N‐glycans, higher levels of fucosylated and sialylated glycans and a truncated O‐glycan phenotype. This abundant cancer glycosylation profile is currently considered a hallmark of cancer [2](#cjp288-bib-0002){ref-type="ref"}. It is assumed that tumour‐associated O‐glycans not only support tumour growth, but are a major factor underlying the development of an immune suppressive tumour microenvironment and actively contribute to immune evasion [1](#cjp288-bib-0001){ref-type="ref"}. In line with this pathophysiology, a shortened O‐glycan phenotype was identified for tumour‐associated bone sialoprotein (BSP) [3](#cjp288-bib-0003){ref-type="ref"} and termed hypoglycosylated BSP (hypo‐BSP).

BSP is a secreted, sialic acid‐rich, phosphorylated glycoprotein with an apparent molecular mass of 70--80 kDa [3](#cjp288-bib-0003){ref-type="ref"}. It belongs to the small integrin‐binding ligand N‐linked glycoprotein (SIBLING) family of proteins and is part of the major non‐collagenous organic matrix fractions in bone [4](#cjp288-bib-0004){ref-type="ref"}. Physiologically, BSP is synthesized by osteoblasts, osteoclasts, osteocytes, and chondrocytes [5](#cjp288-bib-0005){ref-type="ref"} and contains an Arg‐Gly‐Asp (RGD) sequence located in the C‐terminus of the protein, which is a common recognition site for integrins [6](#cjp288-bib-0006){ref-type="ref"}, [7](#cjp288-bib-0007){ref-type="ref"} such as α~V~β~3~ and α~V~β~5~. BSP acts as a promoter for the initial formation of mineral crystals in bone, cementum, and dentine and as an early marker of osteogenic differentiation. In addition to its physiological roles, BSP has been associated with prognosis of breast cancer patients, since elevated serum levels were a marker of subsequent bone metastasis and highly related to poor survival [8](#cjp288-bib-0008){ref-type="ref"}, [9](#cjp288-bib-0009){ref-type="ref"}. BSP was found in primary malignancies such as breast [8](#cjp288-bib-0008){ref-type="ref"}, [10](#cjp288-bib-0010){ref-type="ref"}, prostate [11](#cjp288-bib-0011){ref-type="ref"}, and thyroid cancers [12](#cjp288-bib-0012){ref-type="ref"}. Specifically, the BSP‐mediated interaction between tumour cells and bone tissue was suspected to participate in the pathogenesis of bone metastasis [5](#cjp288-bib-0005){ref-type="ref"}, [8](#cjp288-bib-0008){ref-type="ref"}, [13](#cjp288-bib-0013){ref-type="ref"}, [14](#cjp288-bib-0014){ref-type="ref"}, [15](#cjp288-bib-0015){ref-type="ref"}. BSP enhances migration of cells through matrices by bridging MMP‐2 to α~V~β~3~‐integrin [16](#cjp288-bib-0016){ref-type="ref"}. Beyond that, it is assumed that the secretion of BSP from tumour cells provides a selective advantage for their survival. Here, the RGD motif of BSP binds to the cell surface receptor α~V~β~3~‐integrin and then to complement factor H (cfH), which protects tumour cells from the lytic activity of the complement system [15](#cjp288-bib-0015){ref-type="ref"}.

Based on the observed altered O‐glycan phenotype of tumour‐associated BSP, a set of antibodies was developed that recognize a BSP form which is hypoglycosylated at Thr 125. Here, we report on diagnostic and therapeutic properties of these antibodies against hypo‐BSP in experimental systems and in human pathology samples.

Materials and methods {#cjp288-sec-0002}
=====================

Cell culture {#cjp288-sec-0003}
------------

The non‐tumorigenic immortalized human mammary epithelial cell line MCF‐10 was cultured in Mammary Epithelial Growth Medium (PromoCell, Heidelberg, Germany). The other cell lines (human breast cancer cell lines MDA‐MB‐231^GFP/Luc^ and MCF‐7, human prostate cancer cell line PC3, human osteosarcoma cell line SaOS‐2, human ovarian cancer cell line SK‐OV3) were cultured in Roswell Park Memorial Institute (RPMI)‐1640 medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (FBS), 2 mM [l]{.smallcaps}‐glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen, Germany). The cells were maintained in cell culture flasks (TPP, Switzerland) in an incubator (37 °C, humidified atmosphere, 5% CO~2~). They were propagated 2--3 times per week to keep them in logarithmic growth.

Isolation of monocytes and differentiation to osteoclasts {#cjp288-sec-0004}
---------------------------------------------------------

Monocytes were isolated from peripheral blood as described previously [17](#cjp288-bib-0017){ref-type="ref"} and in supplementary material, Supplementary materials and methods. Cells were stimulated with either RANKL or interleukin‐8 and differentiation was monitored microscopically.

Osteoblast primary culture {#cjp288-sec-0005}
--------------------------

Primary osteoblasts were isolated from spongiosa as described in supplementary material, Supplementary materials and methods.

Monoclonal antibodies {#cjp288-sec-0006}
---------------------

Monoclonal antibodies against BSP were generated as described in supplementary material, Supplementary materials and methods. In brief, the monoclonal rat anti‐BSP antibody IDK‐1 was raised against the hypoglycosylated epitope TGLAA (aa125--130), IDK‐2 was raised against pentameric TGLAA, and IDK‐3 was raised against an epitope of the main and carboxy‐terminal domains of BSP (aa84--318).

Cell proliferation assay (MTT) {#cjp288-sec-0007}
------------------------------

The 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium‐bromide (MTT) assay was used as described previously [18](#cjp288-bib-0018){ref-type="ref"} and in supplementary material, Supplementary materials and methods to assess an anti‐proliferative effect on tumour cells.

Migration assay {#cjp288-sec-0008}
---------------

Cell migration in response to antibody exposure was determined as described previously [18](#cjp288-bib-0018){ref-type="ref"} and in supplementary material, Supplementary materials and methods.

Cytofluorometry {#cjp288-sec-0009}
---------------

Expression of mature BSP and hypo‐BSP was tested as published previously [19](#cjp288-bib-0019){ref-type="ref"} and described in supplementary material, Supplementary materials and methods.

Immunoblotting {#cjp288-sec-0010}
--------------

Immunoblotting was performed as published previously [20](#cjp288-bib-0020){ref-type="ref"} and described in supplementary material, Supplementary materials and methods.

Affinity of antibodies {#cjp288-sec-0011}
----------------------

Microscale thermophoresis was used to determine the binding affinity of antibodies to BSP forms. Experiments were performed according to the protocol (Monolith NT™ Protein Labelling Kit) and as described in supplementary material, Supplementary materials and methods. The dissociation constant (KD) describing the binding affinity of antibodies was calculated using the software NTAnalysis 1.5.41 from NanoTemper^®^ Technologies GmbH.

Animals and husbandry {#cjp288-sec-0012}
---------------------

Male nude rats \[Rowett nude rat (RNU) strain\] were obtained at an age of 5--6 weeks from commercial sources and kept as described previously [21](#cjp288-bib-0021){ref-type="ref"}.

Ethics statement {#cjp288-sec-0013}
----------------

All animal experiments were carried out in accordance with the recommendations in the Guide for the Management Ordinance of Laboratory Animals of the Society of Laboratory Animals (GV‐SOLAS, Germany). The protocols were approved by the Regierungspräsidium Karlsruhe, Germany. All surgeries were performed under anaesthesia, and all efforts were made to minimize suffering.

Tumour cell inoculation {#cjp288-sec-0014}
-----------------------

MDA‐MB‐231^GFP/Luc^ tumour cells were injected into the femoral artery of nude rats as described previously [21](#cjp288-bib-0021){ref-type="ref"} and in supplementary material, Supplementary materials and methods.

Bioluminescence imaging, magnetic resonance imaging, and computed tomography {#cjp288-sec-0015}
----------------------------------------------------------------------------

The appearance and development of bone metastases were monitored by imaging methods, as described previously [21](#cjp288-bib-0021){ref-type="ref"}, [22](#cjp288-bib-0022){ref-type="ref"}.

Immunocytochemistry {#cjp288-sec-0016}
-------------------

Experiments were performed in Lab Tec^TM^ chamber slides^TM^. The cells were fixed in paraformaldehyde (4%, in PBS) and subjected to immunostaining \[4\',6‐diamidino‐2‐phenylindole (DAPI) plus one or two antibodies\] as described in supplementary material, Supplementary materials and methods. In addition to primary antibodies (mouse monoclonal A4232.2 against mature BSP; rat monoclonal IDK‐1 against hypo‐BSP; rabbit polyclonal antibody against human complement cfH, and rabbit polyclonal antibody against human integrin α~V~β~3~) the corresponding tetramethylrhodamine (TRITC)‐ or fluorescein isothiocyanate (FITC)‐conjugated secondary antibodies were used. After staining with antibodies, cell preparations were counterstained with DAPI (Serva), diluted 1:1000 and cover‐slipped. Visualization and image processing are described in detail in supplementary material, Supplementary materials and methods.

Immunohistochemistry {#cjp288-sec-0017}
--------------------

Immunohistochemistry was performed in general as described previously [23](#cjp288-bib-0023){ref-type="ref"}; details of the newly established procedures with the anti‐BSP antibodies are described in supplementary material, Supplementary materials and methods.

Evaluation procedure {#cjp288-sec-0018}
--------------------

The results were evaluated by a pathologist (IB) for lesion severity, intensity of staining, and percentage of positive cells after inspection of all fields in the tissue sections. For evaluation of the ductal structures, sections were scanned at low (×50) magnification. Analysis and semi‐quantitative evaluation were performed using an Axioplan‐2 microscope (Carl Zeiss, Jena, Germany). Semi‐quantitative evaluation was based on quantity of tumour cells (scores 1--4) and colour intensity (scores 1--3), the results of which were multiplied to yield results ranging from 1 to 12.

Patient selection and ethics {#cjp288-sec-0019}
----------------------------

Samples from 11 human primary breast tumours and their corresponding skeletal metastases were obtained by random selection from the archives of the Institute of Pathology, Kassel, Germany. Informed consent of these patients had been obtained at the time of deposition, ranging from 2012 to 2015.

Statistics {#cjp288-sec-0020}
----------

Experimental results were recorded and depicted by their mean and corresponding standard deviation. For proliferation and migration assays, all results were given in percent of the untreated control.

For animal experiments, the bioluminescence imaging (BLI) data were evaluated using the program 'Living Image' (PerkinElmer GmbH, Germany) and the intensity of the emitted photons flux was given by the respective units (photons/s/cm^2^/steradian). This program also converted the numerical values into a pseudo‐colour graphic for visualization of the tumour burden.

Differences between control and treated groups were assessed by the distribution‐independent Kruskal‐Wallis test, which compares rank sums from the respective experimental groups. *P* values ≤ 0.05 were considered significant. Differences in ratios were evaluated by Pearson\'s chi‐squared test (*χ* ^2^).

Results {#cjp288-sec-0021}
=======

Affinity of BSP‐antibodies {#cjp288-sec-0022}
--------------------------

The affinity of BSP‐antibodies to mature and hypo‐BSP was determined by micro‐scale thermophoresis. Based on this method, a control antibody (monoclonal mouse antibody against parathyroid hormone) did not show any affinity towards mature or hypo‐BSP. The mouse monoclonal antibody directed against the C‐terminal part of BSP (aa84--318) showed good affinity for mature BSP (KD = 3.5 × 10^−7^ M) and similar affinity for hypo‐BSP (KD = 4.2 × 10^−7^ M). The rat monoclonal antibody IDK‐1, raised against the hypoglycosylated peptide TGLAA (aa125--130 of BSP) showed moderate affinity (KD = 2.7 × 10^−7^ M) for hypo‐BSP, but negligible affinity for mature BSP (KD = 8.6 × 10^−3^ M). The rat monoclonal antibody IDK‐2, showed distinct affinity for hypo‐BSP (KD = 3.2 × 10^−9^ M) and no affinity for mature BSP. Finally, the rat monoclonal antibody IDK‐3, showed negligible affinity for hypo‐BSP (KD = 7.9 × 10^−3^ M) and a similar affinity for mature BSP (KD = 4.9 × 10^−4^ M). Diagrams showing the corresponding normalized fluorescence versus concentration data are shown in supplementary material, Figure S1.

Effect of BSP‐antibodies on proliferation and migration {#cjp288-sec-0023}
-------------------------------------------------------

For testing whether antibodies directed against hypo‐BSP inhibit basic cellular properties, MDA‐MB‐231^GFP/Luc^ breast cancer cells were exposed for 1--3 days to IDK‐1, IDK‐2, or IDK‐3 concentrations ranging from 100 to 900 µg/ml to determine effects on proliferation, and for 1--4 days to antibody concentrations ranging from 25 to 400 µg/ml, for effects on migration. Under these conditions, neither the proliferation nor the migration of MDA‐MB‐231^GFP/Luc^ cells was inhibited to a discernible degree (supplementary material, Table S1). The same result was obtained when FBS was used without heat inactivation (data not shown).

Subsequently, the anti‐proliferative effect of antibody IDK‐1 was tested in PC3 (human prostate carcinoma) cells and primary human osteoblasts. Similar to MDA‐MB‐231cells, exposure to a concentration of 200 µg/ml for 2--4 days did not change the proliferation of PC3 cells, or that of osteoclasts (similar conditions; data not shown).

To confirm these results by a second method, the percentage of apoptotic and necrotic cells in response to antibody IDK‐1 was determined in MDA‐MB‐231 cells by flow cytometry. Following double staining with Annexin V and propidium iodide, there was no significant increase in apoptotic or necrotic cells following exposure to IDK‐1 (concentration 5--100 µg/ml, 4--24 h). In contrast, exposure to formalin as necrosis inducing agent caused an increase in necrotic cells from 13% to 81% within 60 min (supplementary material, Figure S2A).

Effect of anti‐BSP antibodies *in vivo* {#cjp288-sec-0024}
---------------------------------------

Growth of soft tissue and skeletal lesions was monitored by bioluminescence and magnetic imaging as well as computed tomography (CT). A representative control rat is shown in supplementary material, Figure S3. The three monoclonal rat antibodies against hypo‐BSP were investigated in rats for their effect against MDA‐MB‐231^GFP/Luc^‐induced skeletal lesions as well as the surrounding soft tumour tissue (see Table [1](#cjp288-tbl-0001){ref-type="table-wrap"}). Initially, treatment started 2 weeks after tumour cell inoculation via the femoral artery of a rat\'s hind leg. The antibody treatment was administered twice weekly for 6 weeks and caused differential types of response. Either there was a time‐dependent continuous increase in soft tumour growth, as indicated by increasing light emission, as for untreated controls (Figure [1](#cjp288-fig-0001){ref-type="fig"}A--C), which was termed 'progressive disease'. This response corresponded to an increasing mass of soft tumour tissue concomitantly with growing osteolytic lesions (Figure [1](#cjp288-fig-0001){ref-type="fig"}D, CT‐reconstruction), which caused premature euthanasia of the animals for ethical reasons.

###### 

Experimental design and results of treating nude rats implanted with MDA‐MB‐231^Luci/RFP^ breast cancer cells with antibodies directed against hypoglycosylated BSP

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group   Rat no.\   Treatment                                           Start of treatment after tumour inoculation   Progressive disease\   Stable disease/partial remission\   Complete remission\   Death during treatment period\
          *N* (%)                                                                                                      *N* (%)                *N* (%)                             *N* (%)               *N* (%)
  ------- ---------- --------------------------------------------------- --------------------------------------------- ---------------------- ----------------------------------- --------------------- --------------------------------
  I a     10 (100)   Control[a](#cjp288-note-0001){ref-type="fn"}        2 weeks                                       9 (90)                 0 (0)                               1 (10)                0 (0)

  I b     10 (100)   IDK‐1;\                                             2 weeks                                       1 (10)                 1 (10)                              8 (80)                0 (0)
                     5 mg/kg[b](#cjp288-note-0002){ref-type="fn"}                                                                                                                                       

  II a    10 (100)   Control[a](#cjp288-note-0001){ref-type="fn"}        2 weeks                                       10 (100)               0 (0)                               0 (0)                 0 (0)

  II b    10 (100)   IDK‐2;\                                             2 weeks                                       0 (0)                  1 (10)                              6 (60)                3 (30)
                     5 mg/kg[b](#cjp288-note-0002){ref-type="fn"}                                                                                                                                       

  III a   10 (100)   Control[a](#cjp288-note-0001){ref-type="fn"}        2 weeks                                       10 (100)               0 (0)                               0 (0)                 0 (0)

  III b   10 (100)   IDK‐3;\                                             2 weeks                                       6 (60)                 3 (30)                              1 (10)                0 (0)
                     5 mg/kg[b](#cjp288-note-0002){ref-type="fn"}                                                                                                                                       

  IV a    10 (100)   Control[a](#cjp288-note-0001){ref-type="fn"}        4 weeks                                       10 (100)               0 (0)                               0 (0)                 0 (0)

  IV b    10 (100)   IDK‐1;\                                             4 weeks                                       0 (0)                  4 (40)                              6 (60)                0 (0)
                     5 mg/kg[b](#cjp288-note-0002){ref-type="fn"}                                                                                                                                       

  V a     10 (100)   Control[a](#cjp288-note-0001){ref-type="fn"}        4 weeks                                       10 (100)               0 (0)                               0 (0)                 0 (0)

  V b     10 (100)   IDK‐2;\                                             4 weeks                                       0 (0)                  1 (10)                              5 (50)                4 (40)
                     5 mg/kg[b](#cjp288-note-0002){ref-type="fn"}                                                                                                                                       

  VI a    8 (100)    Control[a](#cjp288-note-0001){ref-type="fn"}        2 weeks                                       8 (100)                0 (0)                               0 (0)                 0 (0)

  VI b    8 (100)    IDK‐1;\                                             2 weeks                                       0 (0)                  3 (37.5)                            5 (62.5)              0 (0)
                     5 mg/kg[b](#cjp288-note-0002){ref-type="fn"}                                                                                                                                       

  VI c    8 (100)    IDK‐1;\                                             2 weeks                                       2 (25)                 3 (37.5)                            3 (37.5)              0 (0)
                     2.5 mg/kg[b](#cjp288-note-0002){ref-type="fn"}                                                                                                                                     

  VII a   6 (100)    Control[a](#cjp288-note-0001){ref-type="fn"}        2 weeks                                       6 (100)                0 (0)                               0 (0)                 0 (0)

  VII b   6 (100)    Pretreatment[c](#cjp288-note-0003){ref-type="fn"}   2 weeks                                       1 (16.7)               0 (0)                               5 (83.3)              0 (0)

  VII c   6 (100)    Pretreatment[d](#cjp288-note-0004){ref-type="fn"}   2 weeks                                       2 (33.3)               1 (16.7)                            3 (50)                0 (0)

  VII d   6 (100)    Pretreatment[e](#cjp288-note-0005){ref-type="fn"}   2 weeks                                       1 (16.7)               0 (0)                               5 (83.3)              0 (0)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Control animals received 0.9% NaCl injections.

Dose was administered twice weekly for 6 weeks.

Tumour cells were pre‐incubated with IDK‐1 (50 µg/ml) for 3 days before inoculation.

Animals were pre‐treated with IDK‐1 (2 × 5 mg/kg) 1 week before tumour cell inoculation.

Tumour cells were pre‐incubated and the animals were pre‐treated with IDK‐1 (combination of ‡ and §).

![BLI and CT for soft tumour and skeletal lesions in control and antibody‐treated rats inoculated with MDA‐MB‐231 breast cancer cells. Nude rats were implanted with MDA‐MB‐231^Luc/RFP^ cells via the femoral artery of their right hind leg. BLI and CT were used for monitoring soft tumour size and extent of skeletal lesions. For BLI, rats were injected with luciferin and the resulting light emission from tumour cells marked with the luciferase gene was recorded. Control rats (A--C) showed a steady increase in tumour size as indicated by light emission (red: most intense, blue: least intense). Antibody‐treated rats showed either a steady tumour size (E--G) or a complete remission, indicated by the disappearance of light signals (I--K). At the end of the observation period, the status of soft tumour lesions was correlated with that of skeletal lesions as determined by CT (D, H, L). A graph (M) showing experimental time in weeks versus intensity of photon emission (p/s/cm^2^/sr) compares representative animals with progressive disease (PD, red) with stable disease (SD, black) and rats showing complete remission (CR, blue).](CJP2-4-55-g001){#cjp288-fig-0001}

Alternatively, the tumour growth was halted, as shown by the respective light emission, which did not increase further (Figure [1](#cjp288-fig-0001){ref-type="fig"}E--G) and this type of response was termed 'no change'. Finally, the light emission of the tumour died out (Figure [1](#cjp288-fig-0001){ref-type="fig"}I--K) and this indicated a 'complete remission' of both soft tumour tissue and osteolytic lesions as confirmed by CT (Figure [1](#cjp288-fig-0001){ref-type="fig"}L) and subsequent histology (supplementary material, Figure S4). The observed changes in tumour growth were measured by BLI and are shown in Figure [1](#cjp288-fig-0001){ref-type="fig"}M.

Administration of IDK 1--3 at 5 mg/kg concentrations started 2 weeks after tumour cell inoculation and was continued twice weekly for 6 weeks (Table [1](#cjp288-tbl-0001){ref-type="table-wrap"}, groups I--III). Remarkably, IDK‐1 caused complete remission in 8 of 10 rats, and no change or progressive disease in 1 of 10 rats, respectively. IDK‐3 was distinctly less effective, as shown by complete remission in 1 of 10 rats, no change in 3 of 10 rats, and progressive disease in 6 of 10 rats. IDK‐2 was also less effective than IDK‐1, but more toxic than the other two antibodies as shown by complete remission in 6 of 10 rats and death related to IDK‐2 toxicity in 3 of 10 animals. In comparison, there was progressive tumour growth in 29 of 30 control rats, corresponding to a spontaneous remission rate of 3%. Because of insufficient efficacy, IDK‐3 was omitted from further analysis.

In subsequent experiments, the time after tumour inoculation until onset of treatment was prolonged from 2 to 4 weeks (Table [1](#cjp288-tbl-0001){ref-type="table-wrap"}, groups IV and V). As a result, 6 of 10 rats treated with IDK‐1 showed complete remission, and 4 of 10 animals showed partial remission or no change. This contrasted to 5 complete and 1 partial remissions out of 10 rats following IDK‐2, as well as 4 of 10 animals dying due to toxicity within the treatment period. In these experiments, all 20 control rats showed progressive disease.

After excluding IDK‐2 from subsequent experiments for its toxicity, IDK‐1 was investigated for its dose‐effect relationship (Table [1](#cjp288-tbl-0001){ref-type="table-wrap"}, groups VI a--c). In fact, administration of a dose reduced by 50% (2.5 mg/kg twice weekly for 6 weeks) was associated with complete remission in 3 of 8 rats, no change in 3 of 8 rats, and progressive disease in 2 of 8 rats. Again, 8 of 8 control rats showed progressive disease.

Finally, neither pre‐treatment of MDA‐MB‐231^GFP/Luc^ cells *in vitro*, nor administration of IDK‐1 to rats prior to tumour cell inoculation, nor the combination of these two types of 'additive' therapy increased the rate of complete remissions to ratios higher than those observed when starting the IDK‐1 treatment at 2 weeks following tumour inoculation (80%).

Flow cytometry detection of BSP‐forms in tumour cell lines {#cjp288-sec-0025}
----------------------------------------------------------

The presence of mature and hypo‐BSP was analysed with the mouse monoclonal antibody (A4232.2) and the rat monoclonal antibody IDK1 (both from Immundiagnostik, Bensheim, Germany) by flow cytometry in MDA‐MB‐231, SaOS‐2, and SK‐OV‐3 tumour cells. All cells expressed both forms of BSP intra‐cellularly at low levels, but at their surface BSP expression was seen only for SK‐OV‐3 cells (supplementary material, Figure S2B).

Immunocytochemistry {#cjp288-sec-0026}
-------------------

### Detection of BSP‐forms in a panel of tumour cell lines {#cjp288-sec-0027}

Cells of the immortal but non‐tumourigenic MCF‐10 line and those of the tumourigenic but not metastatic MCF‐7 line were small or medium sized. No expression of cfH or integrin α~V~β~3~ was detected (data not shown). In addition, traces of hypo‐BSP and slight to moderate expression of mature BSP were detected (Figure [2](#cjp288-fig-0002){ref-type="fig"}A--F). The morphology of MDA‐MB‐231and PC3 cells varied strongly from small, mono‐nuclear cells to mono‐ or poly‐nuclear cells with abundant cytoplasm. Increased expression of all investigated antigens could be found in a fraction of cells derived from both cell lines. The expression pattern of mature BSP and hypo‐BSP was inversely related to that of the non‐metastatic cells (Figure [2](#cjp288-fig-0002){ref-type="fig"}G--L). At higher magnification, the level of mature BSP was higher in small‐ and medium‐sized cells, both intra‐ and extra‐cellularly, when comparing their status to that of the non‐metastatic cells. Hypo‐BSP could be found in large metastatic cells. Small metastatic cells did not express hypo‐BSP; medium‐sized cells showed various patterns of both, hypo‐BSP and mature BSP expression. In large cells, hypo‐BSP was always accompanied by mature BSP, mainly located extra‐cellularly. In special cases, hypo‐BSP was detected in the nucleus. In these cases, mature BSP was only detectable extra‐cellularly. The distribution pattern of both mature BSP (intra‐cellular and extra‐cellular) and hypo‐BSP (no LSM evidence for extra‐cellular distribution) was identical for MDA‐MB‐231 and PC3 cells (Figure [2](#cjp288-fig-0002){ref-type="fig"}G--L).

![Double‐fluorescence analysis of hypo‐BSP and mature BSP. The non‐cancer cell line MCF10 served as control and showed slight to moderate staining for BSP and traces of hypo‐BSP (A--C). Hypo‐BSP was low and mature BSP was slightly to moderately expressed in non‐metastatic MCF7 cells (D--F). In contrast, metastasizing breast (MDA‐MB‐231; G--I) and prostate (PC3; J--L) cancer cells showed intensive staining of hypo‐BSP (arrows), but only little staining for mature BSP. All images were taken at identical microscopic parameters and processed equally.](CJP2-4-55-g002){#cjp288-fig-0002}

These observations were confirmed by results from the confocal laser scanning microscope, which was used for detecting the expression of mature BSP and hypo‐BSP in MDA‐MB‐231 and PC3 cells (Figure [3](#cjp288-fig-0003){ref-type="fig"}A--D). For multiple staining, the green colour in the micrographs indicates hypo‐BSP expression, whereas the presence of mature BSP, cfH, and integrin α~V~β~3~ was visualized by red colour, respectively. Cell nuclei are shown by blue fluorescence.

![Co‐localization of hypo‐BSP and mature BSP as well as with possible interaction partners. Co‐localization of hypoglycosylated BSP (hypo‐BSP) (visualized with FITC; green colour) with (A) complement factor H (cfH) or (B) the vitronectin receptor (α~V~β~3~) (visualized with TRITC; red colour) in MDA‐MB‐231 cells. (C, D) Confocal laser scanning analysis of PC3 and MDA‐MB‐231 cells. Mature BSP (red) and hypo‐BSP (green) show only partial co‐localization (orange colour). In many cells, hypo‐BSP was also observed within the nucleus, while mature BSP was clearly restricted to the perinuclear region, sparing the nucleus (arrows in C). The expression pattern varied within the cell population, i.e. not all of the cells showed hypo‐BSP and mature BSP double‐staining (asterisk in C). Laser scanning features demonstrate the similarities in the PC3 and MDA‐MB‐231 cells. (E--G) Three‐dimensional visualization of a 36 image stack obtained by laser scanning microscopy of a MDA‐MB‐231 cell. Note the patchy distribution of mature BSP (red) mainly on the cell surface, while hypo‐BSP (green) shows granular distribution in the cytoplasm and the kidney‐shaped nucleus. (H--K) Detection of mature BSP and hypo‐BSP in human osteoclasts (H, I: red arrows) and osteoblasts growing in the presence of collagen I (J, K: collagen indicated by red colour). In both skeletal cell types the cytosol stained positive for mature BSP, which is shown by green fluorescence (H, J) but was negative for hypo‐BSP (I, K).](CJP2-4-55-g003){#cjp288-fig-0003}

Nearly all of the stained cells expressed cfH and integrin α~V~β~3~ (Figure [3](#cjp288-fig-0003){ref-type="fig"}A,B). Completely green tinted cells (indicating hypo‐BSP) showed smaller amounts of cfH, indicated by a yellow‐orange colour (Figure [3](#cjp288-fig-0003){ref-type="fig"}A). The expression of integrin α~V~β~3~ was comparable to that of cfH, as the expression was present in all cells. In the large hypo‐BSP expressing cells, the co‐localization of α~V~β~3~ and hypo‐BSP is indicated by yellow‐orange colour (Figure [3](#cjp288-fig-0003){ref-type="fig"}B). It seems that smaller cells contained more red colour, indicating the presence of cfH and integrin α~V~β~3~ without hypo‐BSP. Concomitant expression of mature (red) and hypo‐BSP was examined in PC3 (Figure [3](#cjp288-fig-0003){ref-type="fig"}C) and MDA‐MB‐231 (Figure [3](#cjp288-fig-0003){ref-type="fig"}D) cells. Within the cell populations, the expression pattern varied, as not all cells showed double staining. In cells showing red and green stains, there was only partial co‐localization (orange colour). In many of the positive cells, hypo‐BSP was present within the nucleus, whereas mature BSP was restricted to the perinuclear region, sparing the nucleus. Three‐dimensional visualization of BSP expression was performed in MDA‐MB‐231 cells only (Figure [3](#cjp288-fig-0003){ref-type="fig"}E--G). Mature BSP showed a patchy distribution mainly on the cell surface, but hypo‐BSP showed a granular distribution in the cytoplasm and the nucleus.

### Detection of BSP‐forms in osteoblasts and osteoclasts {#cjp288-sec-0028}

In addition, the presence of BSP forms was analysed by immunocytochemistry in human osteoclasts (Figure [3](#cjp288-fig-0003){ref-type="fig"}H,I) and osteoblasts growing in the presence of collagen I (Figure [3](#cjp288-fig-0003){ref-type="fig"}J,K; collagen indicated by red colour). In both skeletal cell types, the cytosol stained positive for mature BSP, which is shown by green fluorescence (Figure [3](#cjp288-fig-0003){ref-type="fig"}H,J) but was negative for hypo‐BSP (Figure [3](#cjp288-fig-0003){ref-type="fig"}I,K).

Detection of BSP‐forms by immunohistochemistry {#cjp288-sec-0029}
----------------------------------------------

The two monoclonal antibodies were also compared for their staining patterns in samples obtained from lesions growing in nude rats following either subcutaneous or intra‐arterial (femoral artery) injection of MDA‐MB‐231^GFP/Luc^ cells. In contrast to cell culture conditions, mature BSP was detected by the mouse monoclonal antibody (A4232.2) to be abundantly expressed in and around MDA‐MB‐231^GFP/Luc^ cells growing subcutaneously (Figure [4](#cjp288-fig-0004){ref-type="fig"}A[1](#cjp288-fig-0001){ref-type="fig"},A2) and as soft tumour around the femur (Figure [4](#cjp288-fig-0004){ref-type="fig"}B[1](#cjp288-fig-0001){ref-type="fig"},B2). Extraordinary intra‐cellular production was also associated with vesicles filled with BSP, which were found in the extra‐cellular space.

![Immunostaining of MDA‐MB‐231 breast cancer cell‐derived tumours. Mature BSP was stained with mouse monoclonal antibody A4232.2. The upper row (A1, A2) shows a tumour growing subcutaneously (left image: ×20 objective magnification, right image: ×63 objective magnification). The lower row (B1, B2) shows tumour growing adjacent to rat femur (left image: ×20 objective magnification, right image: ×63 objective magnification). Nuclei are stained blue; BSP is indicated by brown colour. Distinct granular cytoplasmic expression of mature BSP is found under both conditions. At higher magnification, vesicles filled with mature BSP are found in the extra‐cellular space. Hypoglycosylated BSP was stained with rat monoclonal antibody IDK‐1. The upper row (C1, C2) shows a tumour growing subcutaneously (left image: ×20 objective magnification, right image: ×63 objective magnification). The lower row (D1, D2) shows tumour growing adjacent to rat femur (left image: ×20 objective magnification, right image: ×63 objective magnification). Nuclei are stained blue; hypoglycosylated BSP is indicated by brown colour. Local diffuse cytoplasmic expression of hypoglycosylated BSP is found in tumours growing subcutaneously; in contrast, distinct granular expression of hypoglycosylated BSP is observed in tumour growing adjacent to bone tissue.](CJP2-4-55-g004){#cjp288-fig-0004}

Compared to the mouse monoclonal antibody, the rat monoclonal antibody IDK‐1 stained the tumour growing subcutaneously much less intensely (Figure [4](#cjp288-fig-0004){ref-type="fig"}C[1](#cjp288-fig-0001){ref-type="fig"},C2), but soft tumour tissue in the vicinity of the skeleton with similar intensity (Figure [4](#cjp288-fig-0004){ref-type="fig"}D[1](#cjp288-fig-0001){ref-type="fig"},D2). Notably, hypo‐BSP was also stained intensely in necrotic areas of tumours growing *in vivo* (supplementary material, Figure S5). IDK‐1 staining indicated distinct granular expression of hypo‐BSP.

In addition to human breast cancer cells growing in nude rats, IDK‐1 was also used for staining the primary tumour and respective skeletal metastases of 11 breast cancer patients. When assessing the IDK‐1 staining intensity by a semi‐quantitative score, primary lesions had an average score of 4.5 indicating hypo‐BSP expression, but skeletal lesions had an average score of 8.3. This increase was highly significant when comparing the scoring results by the Wilcoxon rank sum test (*p* \< 0.004). Tumour and metastasis samples from two breast cancer patients are shown in Figure [5](#cjp288-fig-0005){ref-type="fig"}. The photographs shown in Figure [5](#cjp288-fig-0005){ref-type="fig"}A--D are taken from a 45‐year‐old patient with a grade 2. The level of hypo‐BSP increased from moderate local expression in the primary tumour (Figure [5](#cjp288-fig-0005){ref-type="fig"}B) to diffusely distributed moderate cytoplasmic expression in the corresponding metastasis (Figure [5](#cjp288-fig-0005){ref-type="fig"}D). The photographs in Figure [5](#cjp288-fig-0005){ref-type="fig"}E--H are taken from a 47‐year‐old patient with ductal breast cancer. Here, the hypo‐BSP level increased from focal, moderate cytoplasmic expression (Figure [5](#cjp288-fig-0005){ref-type="fig"}F) to diffuse distribution of moderate to strong cytoplasmic expression (Figure [5](#cjp288-fig-0005){ref-type="fig"}H). An overview of eleven breast cancer patients with their grades and receptor status as well as a score describing the staining intensity of BSP in the primary cancer versus metastatic skeletal lesions is given in supplementary material, Table S2. The score intensity was significantly higher in metastatic than in primary lesions (*p* \< 0.004).

![Immunostaining of specimens from breast cancer patients. Mucinous, grade 2 breast cancer of a 45‐year‐old female patient (ER positive, PR weakly positive, Her2 negative; (A) HE stain of the primary carcinoma (×10 objective magnification); (B) hypo‐BSP stain of the primary carcinoma with rat monoclonal antibody IDK‐1 (×20 objective magnification) showing moderate local expression; (C) HE stain of metachronous (7 years) spinal metastasis (thoracic vertebrae 3 + 4, ×4 objective magnification); (D) hypo‐BSP stain of a metachronous (7 years) spinal metastasis with rat monoclonal antibody IDK1 (×40 magnification) showing diffuse distribution of moderate cytoplasmic hypo‐BSP expression. Invasive, grade 2 ductal breast cancer of a 47‐year‐old female patient (ER strongly positive, PR strongly positive, Her2 negative; (E) HE stain of the primary carcinoma (×4 objective magnification); (F) hypoglycosylated BSP stain of the primary carcinoma with rat monoclonal antibody IDK1 (×4 objective magnification) showing focal, moderate cytoplasmic expression; (G) HE stain of a synchronous spinal metastasis (thoracic vertebra 6, ×20 objective magnification); (H) hypoglycosylated BSP stain of a synchronous spinal metastasis with rat monoclonal antibody IDK1 (×20 objective magnification) showing diffuse distribution of moderate to strong cytoplasmic expression.](CJP2-4-55-g005){#cjp288-fig-0005}

Specificity of IDK1 {#cjp288-sec-0030}
-------------------

The specificity of IDK1 was assessed in whole cell lysates from MDA‐MB‐231 cells grown *in vitro* and *in vivo* (the latter isolated from a breast cancer skeletal metastasis growing in a nude rat). Immunoblotting for hypo‐BSP showed a 3.6‐fold increased level of BSP expression between cells growing *in vitro* and *in vivo*. Similarly, all three histone demethylases (histone lysine demethylase PHF8, lysine‐specific demethylase 3B \[KDM3B\], and lysine‐specific demethylase PHF2), which contain the IDK1 target sequence TGLAA, were detected with their specific antibodies, but not with IDK1, as there were no bands visible that showed a size similar to that of the demethylases (supplementary material, Figure S6).

Cross‐reaction with murine BSP {#cjp288-sec-0031}
------------------------------

To further characterize the specificity of IDK1, the femur of a mouse was stained with IDK1 for hypo‐BSP. There was no staining of any structure, including osteoblasts and osteoclasts (data not shown).

Discussion {#cjp288-sec-0032}
==========

Post‐translational modifications including glycosylation profiles can change significantly during oncogenesis [24](#cjp288-bib-0024){ref-type="ref"} and represent a promising source for potential biomarkers [25](#cjp288-bib-0025){ref-type="ref"}. For example, breast cancer patients can secrete MUC1 glycoprotein with *O*‐linked oligosaccharides, which differs from that of healthy tissues [26](#cjp288-bib-0026){ref-type="ref"} and this altered glycosylation is used for detecting breast cancer. The use of an altered glycosylation pattern as a biomarker for cancer diagnostics is only one example of a growing area [25](#cjp288-bib-0025){ref-type="ref"}. Here, we add hypo‐BSP to this list of markers and show concomitantly the potential of this glycoprotein as a target for treating skeletal metastasis.

The monoclonal rat antibody IDK1 showed good affinity for hypo‐BSP, but none for mature BSP and induced higher rates of complete remission in nude rats harbouring MDA‐MB‐231‐induced skeletal lesions than a polyclonal IgY antibody against BSP that was used previously [27](#cjp288-bib-0027){ref-type="ref"}. In contrast to the IgY antibody, IDK1 was not cytotoxic *in vitro*. This observation and the finding that MDA‐MB‐231 cells secrete large amounts of both BSP forms only *in vivo* shed some light on the putative mechanism of action of IDK1. We assume that hypo‐BSP, which was preferentially produced in the vicinity of the rat skeleton, is involved in the formation of lytic skeletal lesions. The capture of hypo‐BSP by IDK1, similar to a decoy receptor, may then have decreased this effect. This hypothesis does not exclude that complexes of IDK1 and hypo‐BSP are located on the membrane of tumour cells and induced complement activation, which has been described in nude rats [28](#cjp288-bib-0028){ref-type="ref"}. This reaction could be initiated by binding of BSP to integrin α~V~β~3~, which is amply present on MDA‐MB‐231 cells (Figure [3](#cjp288-fig-0003){ref-type="fig"}B). Based on this, integrin α~V~β~3~ has been successfully targeted by its inhibitor cilengitide and this treatment correlated with significant growth inhibition of MDA‐MB‐231 skeletal metastases [29](#cjp288-bib-0029){ref-type="ref"}. Despite the presence of α~V~β~3~, our FACS analyses showed no BSP on the surface of MDA‐MB‐231 cells growing in cell culture. Although this could be different *in vivo* because of the increased expression of BSP, the lack of any anti‐proliferative activity of IDK1, even in experiments using FBS without heat inactivation, lowers the probability that complement activation is a decisive factor in the mechanism of action of IDK1. Moreover, the abundant presence of cfH on MDA‐MB‐231 cells (Figure [3](#cjp288-fig-0003){ref-type="fig"}A) could be interpreted as part of their immune evasion strategy [30](#cjp288-bib-0030){ref-type="ref"} and further add to the lack of complement activation.

The expression of mature and hypo‐BSP in cells growing *in vitro* was low, even in the metastatic cell line MDA‐MB‐231. However, when comparing selected cells positive for BSP, there was more expression of hypo‐BSP in the metastatic cell lines MDA‐MB‐231and PC3 than in non‐metastatic or non‐malignant cells. One typical but puzzling site of hypo‐BSP was the nucleus, whereas mature BSP was mainly prevalent in the perinuclear region. There was also co‐expression and partial co‐localization with cfH and integrin α~v~β~3~, which are potential interaction partners [31](#cjp288-bib-0031){ref-type="ref"}. However, the main sites of BSP expression *in vivo* were cytoplasm and membranes. Nuclei were partially condensed, thus giving rise to assumed low BSP concentrations, but there was no conclusive evidence. The following reasons, nevertheless, might indicate a role of BSP in the nucleus: conditional knockdown of BSP caused not only complete regression of established MDA‐MB‐231 skeletal lesions, but also intensive alterations of cellular signalling cascades and induction of apoptosis [20](#cjp288-bib-0020){ref-type="ref"}. Finally, immunoblotting of nuclear extracts from tumour tissue growing in the vicinity of skeletal lesions showed a strong band indicative of hypo‐BSP. This could imply a role of BSP that has not been unravelled so far. An alternative possibility is the presence of other proteins containing the TGLAA motif, including the histone demethylases PHF8, KDM3B, and PHF2, which are nuclear constituents. Thus, only future experiments will shed light on these open questions.

In the model used, the activity of IDK1, which induced complete remission in up to 80% of rats, is unsurpassed to the best of our knowledge by any other compound and may alter skeletal metastasis treatment if the results will translate into the clinical situation. The reason for this activity presumably is a change in BSP expression of MDA‐MB‐231 cells under *in vivo* conditions. The poor expression of BSP *in vitro* is dramatically increased *in vivo*, regardless of the site of implantation (Figure [4](#cjp288-fig-0004){ref-type="fig"}). The specificity of IDK1 results, however, from differential expression of hypo‐BSP in primary and metastatic sites: MDA‐MB‐231^GFP/Luc^ tumours growing subcutaneously express large amounts of mature BSP, but only few hypo‐BSP. In concordance with this observation, IDK1 has little activity in MDA‐MB‐231^GFP/Luc^ tumours growing subcutaneously, but impressive activity at skeletal site lesions, which are characterized by large amounts of hypo‐BSP. These observations are related to the human pathology, as tissues from skeletal metastases expressed significantly more hypo‐BSP than those from the respective primary breast cancers. Notwithstanding this congruency of animal model and human pathologies, some caveats are needed for interpreting the results. The use of a T‐cell deficient model for screening immunotherapeutic agents has restrictions as these models are not applicable for studying checkpoint blockers [32](#cjp288-bib-0032){ref-type="ref"}. However, the use of syngeneic mouse models was excluded due to the lack of IDK1 cross‐reactivity with mouse BSP (unpublished own data) and, likewise, the use of humanized models was precluded by their availability. It should be kept in mind, however, that the putative mechanism of action does not include the activity of T‐cells and that using IDK1 for capturing hypo‐BSP has analogies to using denosumab as a decoy receptor of RANKL [33](#cjp288-bib-0033){ref-type="ref"}, [34](#cjp288-bib-0034){ref-type="ref"}. Another aspect of the model is that side effects on the skeleton cannot be predicted sufficiently because of the species differences in BSP composition. Our initial results suggest no interaction of IDK1 with human osteoblasts and osteoclasts, but future experiments will have to elucidate any toxic effect of IDK1 on human bone physiology.

In conclusion, hypo‐BSP is a promising biomarker of skeletal metastasis, which can be used for diagnostic purposes. After transforming this monoclonal rat antibody into a human version, it can also be tested for its potential application in patients. If the encouraging results of this study translate into clinical application, a new treatment option for skeletal metastases will be available. Such studies are highly warranted.
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**Figure S1.** Affinity of antibodies to bone sialoprotein forms. The affinity of monoclonal antibodies of mouse (A, B) or rat (C--G) origin against hypoglycosylated or mature bone sialoprotein (hypo‐BSP or mature BSP) was determined in comparison to a human control antibody against parathyroid hormone (PTH; H, I) by microscale thermophoresis. Measurable affinities in terms of KD values (the equilibrium dissociation constant) are indicated in the corners of the diagrams. The antibody designation is given to the left of the two columns.
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**Figure S2.** Flow cytometry analysis. (A) Flow cytometry analysis of MDA‐MB‐231 cells exposed to PBS (control, top left), 2% formalin (positive control, top right), rat‐IgG (isogenic protein control, bottom left) and the monoclonal rat antibody IDK‐1 (bottom right). The percentages in the upper right quadrants indicate the respective apoptosis induction. Clearly, IDK‐1 did not elicit apoptosis. (B) The presence of mature and hypo‐glycosylated BSP was detected by flow cytometry analysis with specific antibodies in a panel of three tumour cell lines growing *in vitro* \[thin line unrelated isotype‐specific (negative) control antibody\]. Low signals of BSP (mature and hypo‐glycosylated) were found in all cell lines. However, the cell surface was free of BSP, except for cells of the SK‐OV‐3 cell line.
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**Figure S3.** Growth of MDA‐MB‐231‐induced skeletal lesions in nude rats: comparison of imaging methods. The growth of soft tissue and skeletal lesions was followed in nude rats after intra‐femoral artery implantation of 1 × 10^5^ MDA‐MB‐231 breast cancer cells. Monitoring started 1 week after tumour cell implantation using computed tomography (CT; A, D, G), magnetic resonance imaging (MRI; B, E, H), and bioluminescence imaging (BLI; C, F, I) and was maintained for 5 weeks (the time after tumour implantation is indicated in the lower right corner of A, D, G). Clearly, BLI was the most sensitive detection method. Arrows in D and G denote osteolytic lesions detected by CT.
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**Figure S4.** Histological evaluation of rat hind legs after treatment with IDK‐1. A control rat (A) as well as rats inoculated with MDA‐MB‐231 breast cancer cells (B, C) were treated with IDK‐1. The rat treated with IDK‐1 with the treatment starting 2 weeks after tumour cell inoculation showed complete remission by bioluminescence imaging and no signs of tumour growth upon histological evaluation of respective H&E stains (B). In parallel, the rat treated with IDK‐1 starting at 4 weeks after tumour cell implantation showed a complete remission by bioluminescence imaging as well as by histopathology (C).
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**Figure S5.** Immunehistochemical stain of a partially necrotic MDA‐MB‐231 tumour for hypo‐glycosylated bone sialoprotein. A nude rat was inoculated with MDA‐MB‐231 breast cancer cells. The respective tumour of this control was excised, fixed in 4% formalin and stained for the presence of hypo‐glycosylated bone sialoprotein. The necrotic area of this tumour showed focally intense staining for hypo‐BSP, a sign of non‐specific binding of the primary antibody, as is often present in necrotic areas (20‐fold magnification).
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**Figure S6.** Hypoglycosylated BSP, histone lysine demethylase PHF8, lysine‐specific demethylase 3B (KDM3B), and lysine‐specific demethylase PHF2 in whole cell lysates from MDA‐MB‐231 cells *in vitro* and *in vivo* (the latter isolated from a breast cancer skeletal metastasis growing in a nude rat). The antibody IDK1 detects several bands corresponding to hypo‐BSP, which shows apparent molecular sizes of 38 and 45 kDa (*in vitro*) and of 25, 35, 45, 47, 52 kDa (*in vivo*). The intact histone demethylases PHF8, KDM3B, and PHF2 show larger sizes -- 140, 240, and 120 kDa. They were detected by Abcam antibodies (ab191386, ab70797, and ab1138, respectively). β‐Actin (43 kDa), was used as loading control and was detected by Santa Cruz antibody sc1615. The numbers to the left of each column indicate the molecular size of the protein marker fragments in kDa.
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**Table S1.** Experimental set up and results from testing three monoclonal antibodies against hypo‐BSP for anti‐proliferative and anti‐migratory effects
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**Table S2.** Evaluation of hypo‐BSP staining intensity by semi‐quantitative scoring in 11 paired human samples
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